[
    [
        {
            "time": "2021-06-15",
            "original_text": "【国金医药】创新药周报20210615",
            "features": {
                "keywords": [
                    "国金医药",
                    "创新药",
                    "周报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【国金医药】创新药周报20210615",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-06-17",
            "original_text": "贝达药业：1013.86万股6月17日上市流通，占公司总股本的2.44%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "上市流通",
                    "限售股",
                    "解禁"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：1013.86万股6月17日上市流通，占公司总股本的2.44%",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-17",
            "original_text": "贝达药业(300558.SZ)：1013.86万限售股将于6月17日上市流通 解禁",
            "features": {
                "keywords": [
                    "贝达药业",
                    "限售股",
                    "解禁",
                    "上市流通"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：1013.86万限售股将于6月17日上市流通 解禁",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-17",
            "original_text": "贝达药业：约1013.86万股限售股6月17日解禁，占比2.44% 解禁",
            "features": {
                "keywords": [
                    "贝达药业",
                    "限售股",
                    "解禁"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：约1013.86万股限售股6月17日解禁，占比2.44% 解禁",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-06-14",
            "original_text": "中泰金工定向增发跟踪周报（6/14）",
            "features": {
                "keywords": [
                    "中泰金工",
                    "定向增发",
                    "跟踪周报"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中泰金工定向增发跟踪周报（6/14）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-14",
            "original_text": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
            "features": {
                "keywords": [
                    "太平洋",
                    "医药行业",
                    "周报",
                    "丽珠集团",
                    "我武生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "太平洋-医药行业周报：重点推荐丽珠集团和我武生物【行业研究】",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-01",
            "original_text": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资月报",
                    "窗口期",
                    "配置"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业2021年6月投资月报：6月仍然是较好的窗口期 两条思路配置医药",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]